Market Cap 20.28B
Revenue (ttm) 29.05M
Net Income (ttm) -171.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -592.01%
Debt to Equity Ratio 0.00
Volume 5,013,700
Avg Vol 6,327,342
Day's Range N/A - N/A
Shares Out 715.70M
Stochastic %K 92%
Beta 1.20
Analysts Strong Sell
Price Target $33.25

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7400 3347
Website: roivant.com
Address:
50 Broadway, 7th Floor, London, United Kingdom
TradeTracs
TradeTracs Apr. 5 at 5:55 AM
$ROIV ripping into catalyst territory 🔥 Roivant dropping a slide deck on brepocitinib expansion + Phase III batoclimab data — pipeline fireworks incoming. Stock up 1.76% to $28.33, holding above SMA20 ($28.02) and well extended from SMA50 ($26.62). RSI 56.53 — not overbought, room to run. Up 30.55% QTD from $8.73 lows. Resistance at 52W high $30.33 👀 Break above $30.33 is the key trigger. Watching for volume confirmation — today's vol running light at 0.78x. Clinical data updates can move biotech hard. This one's on the radar. #ROIV #Biotech #ClinicalTrials
0 · Reply
Beach27
Beach27 Apr. 3 at 1:55 PM
$ROIV Gemini said Vanguard change the way they look at total shares from being all under Vanguard to being in all the funds that hold ROIV. Did they really sell?
0 · Reply
DocPharm
DocPharm Apr. 2 at 8:40 PM
$ABUS $ROIV So Whitefort and Vanguard sold all of their ROIV shares Vivek sold about 1/2 of his, along with some other large firms and other execs… Intriguing to say the least
7 · Reply
sheepmanct
sheepmanct Apr. 2 at 9:18 AM
$ROIV Some early morning news releases https://www.immunovant.com/investors/news-events/press-releases/detail/81/immunovant-announces-phase-3-study-results-for-batoclimab https://investor.roivant.com/news-releases/news-release-details/priovant-expands-brepocitinib-development-program-new-phase-2b3 https://investor.roivant.com/news-releases/news-release-details/roivant-announces-expansion-brepocitinib-development-program-new
0 · Reply
AlertsAndNews
AlertsAndNews Mar. 29 at 9:35 PM
$ROIV New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis what a chart here lately too. "Brepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reduction"
0 · Reply
sheepmanct
sheepmanct Mar. 28 at 9:07 PM
$ROIV NEJM article https://investor.roivant.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-phase-3-valor/
0 · Reply
MikiTrader
MikiTrader Mar. 25 at 10:24 PM
$ROIV No wonder it went up.
1 · Reply
DocPharm
DocPharm Mar. 24 at 6:53 PM
$ROIV adding a few Seems off to be down this much Limit still sitting @ 21
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 23 at 10:41 PM
$ROIV RSI: 50.62, MACD: 0.4939 Vol: 0.70, MA20: 28.58, MA50: 25.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Buqqets
Buqqets Mar. 20 at 9:21 PM
$ABUS $ROIV absurd AH volumes and no movement. Options or blatant fuckery? No idea with these anymore.
2 · Reply
Latest News on ROIV
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript

Feb 6, 2026, 3:44 PM EST - 2 months ago

Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript


Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.

Jan 12, 2026, 10:15 PM EST - 2 months ago

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.


Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

Jan 8, 2026, 10:42 AM EST - 3 months ago

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript


Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update

Dec 22, 2025, 11:25 PM EST - 3 months ago

Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update

ALAB RDDT URI


Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript

Dec 12, 2025, 6:12 PM EST - 4 months ago

Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript


Roivant Sciences: Brepocitinib And Roadmap Still Underpriced

Nov 13, 2025, 7:28 AM EST - 5 months ago

Roivant Sciences: Brepocitinib And Roadmap Still Underpriced


Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 12:31 PM EST - 5 months ago

Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript


Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript

Sep 23, 2025, 5:45 AM EDT - 6 months ago

Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript


Roivant Sciences Ltd. - Special Call

Sep 17, 2025, 3:43 PM EDT - 7 months ago

Roivant Sciences Ltd. - Special Call


Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Aug 11, 2025, 12:28 PM EDT - 8 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript


Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 2:17 PM EDT - 11 months ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript


TradeTracs
TradeTracs Apr. 5 at 5:55 AM
$ROIV ripping into catalyst territory 🔥 Roivant dropping a slide deck on brepocitinib expansion + Phase III batoclimab data — pipeline fireworks incoming. Stock up 1.76% to $28.33, holding above SMA20 ($28.02) and well extended from SMA50 ($26.62). RSI 56.53 — not overbought, room to run. Up 30.55% QTD from $8.73 lows. Resistance at 52W high $30.33 👀 Break above $30.33 is the key trigger. Watching for volume confirmation — today's vol running light at 0.78x. Clinical data updates can move biotech hard. This one's on the radar. #ROIV #Biotech #ClinicalTrials
0 · Reply
Beach27
Beach27 Apr. 3 at 1:55 PM
$ROIV Gemini said Vanguard change the way they look at total shares from being all under Vanguard to being in all the funds that hold ROIV. Did they really sell?
0 · Reply
DocPharm
DocPharm Apr. 2 at 8:40 PM
$ABUS $ROIV So Whitefort and Vanguard sold all of their ROIV shares Vivek sold about 1/2 of his, along with some other large firms and other execs… Intriguing to say the least
7 · Reply
sheepmanct
sheepmanct Apr. 2 at 9:18 AM
$ROIV Some early morning news releases https://www.immunovant.com/investors/news-events/press-releases/detail/81/immunovant-announces-phase-3-study-results-for-batoclimab https://investor.roivant.com/news-releases/news-release-details/priovant-expands-brepocitinib-development-program-new-phase-2b3 https://investor.roivant.com/news-releases/news-release-details/roivant-announces-expansion-brepocitinib-development-program-new
0 · Reply
AlertsAndNews
AlertsAndNews Mar. 29 at 9:35 PM
$ROIV New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis what a chart here lately too. "Brepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reduction"
0 · Reply
sheepmanct
sheepmanct Mar. 28 at 9:07 PM
$ROIV NEJM article https://investor.roivant.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-phase-3-valor/
0 · Reply
MikiTrader
MikiTrader Mar. 25 at 10:24 PM
$ROIV No wonder it went up.
1 · Reply
DocPharm
DocPharm Mar. 24 at 6:53 PM
$ROIV adding a few Seems off to be down this much Limit still sitting @ 21
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 23 at 10:41 PM
$ROIV RSI: 50.62, MACD: 0.4939 Vol: 0.70, MA20: 28.58, MA50: 25.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Buqqets
Buqqets Mar. 20 at 9:21 PM
$ABUS $ROIV absurd AH volumes and no movement. Options or blatant fuckery? No idea with these anymore.
2 · Reply
mj6534
mj6534 Mar. 20 at 6:23 PM
$ABUS You know, honestly we all got shafted here by $ROIV and our “CEO”. Anyone remember $TRIL thats the type of move I was expecting here I’m very disappointed.
1 · Reply
DocPharm
DocPharm Mar. 20 at 11:01 AM
0 · Reply
KellyKimberly
KellyKimberly Mar. 16 at 2:48 PM
$ABUS buy $ROIV instead
2 · Reply
TradeTracs
TradeTracs Mar. 15 at 9:23 PM
$ROIV just secured a $2.25 BILLION global settlement resolving COVID vaccine patent litigation over mRNA lipid nanoparticle tech 💰 Non-dilutive cash event. No equity issued. Litigation overhang gone. One of the largest biotech IP resolutions of the COVID era. #Biotech #COVID #Vaccine
0 · Reply
CycleTrade
CycleTrade Mar. 15 at 5:43 PM
Finally today, let's look at another top 100 stock in the US $ROIV which happens to have the lowest 100 day ATR % and thus lowest volatility on the list which is generally what we want for shorter term trading as price will not whipsaw as often as a more volatile stock would. However, I'll backtest it on each of the shorter tactical trading 20EMA channel and the longer strategic 200EMA channel since inception which I beleieve was in 2021. Tactical trading has taken an initial $50,000 up by $77,000, to $127,000 (not too shab), with a max drawdown of just 5.66% and a total of 29 closed trades with an open trade. The longer strategic 200EMA original stake of $50,000 is up by $99,000, so $149,000, with a drawdown of just under 3% and only 7 closed trades with the current one in progress. Excellent!
0 · Reply
mj6534
mj6534 Mar. 13 at 1:47 PM
$ABUS $ROIV really used us man. I knew I should’ve bought it at 3$. I’d be up 1000% instead only up a fraction of that
2 · Reply
jdubya23
jdubya23 Mar. 12 at 3:11 AM
$ABUS $ROIV - AH Volume for ROIV Not sure if anyone noticed but huge volume in AH for ROIV. Over 2.7 million shares traded at 4:17p EST. Price looked like $29.58 which was the closing price. There was also a 366K trade at 5:19p EST. So, over 3 million shares traded in AH. Might be nothing but that was a lot of volume and much more than normal. ABUS had little AH volume of note. Only 20K shares traded.
4 · Reply
WAJeff
WAJeff Mar. 11 at 8:52 PM
$ROIV $30.33 ath and 186% in a year for a stock I never had enough of. Big miss on my part.
1 · Reply
Nile1
Nile1 Mar. 11 at 5:28 AM
$ABUS I believe without the complex ownership structure and $ROIV role, ABUS would likely have already moved above $12 quite easily.
2 · Reply
DocPharm
DocPharm Mar. 10 at 12:29 PM
$BNTX $ABUS $PFE $ROIV BIG OL’ HMMMMM RIGHT HERE
2 · Reply
5htc2
5htc2 Mar. 10 at 1:55 AM
$ROIV wouldn’t mind a Pfizer settlement (LNP) that involved acquiring full ownership of brepocitinib. Pfizer currently has a 25% stake.
0 · Reply
DocPharm
DocPharm Mar. 9 at 5:45 PM
$ABUS $ROIV for dip to add both
0 · Reply